Artificial intelligence (AI) is amplifying the pace of drug development, allowing developers to attack otherwise intractable problems and achieve results in weeks. Previously, results may have been impossible within any time frame.
As an example of the power of AI in drug development, Abraham Heifets, co-founder and CEO of Atomwise, gave the example from a commercial collaborator that was targeting a kinase as a cancer therapeutic. As a panelist at the Demy-Colton Virtual Salon Series, “Drugging the Undruggable: The Power of Artificial Intelligence,” he pointed out that many of the biggest companies in the pharma and biotech industries had pursued that target but all failed because of unacceptable cardiotoxicity.
“AI succeeded. Approximately 99.999% of the molecules available to chemists don’t exist, but are available on demand,” he said.